CN1544637A - Method for preparing mB7.1-GPI fusion proteins and their uses - Google Patents
Method for preparing mB7.1-GPI fusion proteins and their uses Download PDFInfo
- Publication number
- CN1544637A CN1544637A CNA2003101087786A CN200310108778A CN1544637A CN 1544637 A CN1544637 A CN 1544637A CN A2003101087786 A CNA2003101087786 A CN A2003101087786A CN 200310108778 A CN200310108778 A CN 200310108778A CN 1544637 A CN1544637 A CN 1544637A
- Authority
- CN
- China
- Prior art keywords
- gpi
- fusion rotein
- preparation
- tumor
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims description 17
- 108020001507 fusion proteins Proteins 0.000 title abstract description 6
- 102000037865 fusion proteins Human genes 0.000 title abstract description 4
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 45
- 210000004027 cell Anatomy 0.000 claims abstract description 37
- 238000002360 preparation method Methods 0.000 claims abstract description 24
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 16
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 11
- 239000012528 membrane Substances 0.000 claims abstract description 7
- 230000004927 fusion Effects 0.000 claims description 31
- 238000001890 transfection Methods 0.000 claims description 13
- 101100230376 Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) celI gene Proteins 0.000 claims description 12
- 241000699802 Cricetulus griseus Species 0.000 claims description 12
- 210000001672 ovary Anatomy 0.000 claims description 12
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 9
- 230000003321 amplification Effects 0.000 claims description 9
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 9
- 238000004587 chromatography analysis Methods 0.000 claims description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims description 6
- 238000001262 western blot Methods 0.000 claims description 6
- 210000000170 cell membrane Anatomy 0.000 claims description 5
- 239000012634 fragment Substances 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 239000013599 cloning vector Substances 0.000 claims description 4
- 239000012264 purified product Substances 0.000 claims description 4
- 238000012216 screening Methods 0.000 claims description 4
- 108700031361 Brachyury Proteins 0.000 claims description 3
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 3
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 238000000684 flow cytometry Methods 0.000 claims description 2
- 238000001638 lipofection Methods 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 abstract description 24
- 241000699670 Mus sp. Species 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 11
- 108010002350 Interleukin-2 Proteins 0.000 abstract description 8
- 230000004614 tumor growth Effects 0.000 abstract description 4
- 229960005486 vaccine Drugs 0.000 abstract description 4
- 230000006870 function Effects 0.000 abstract description 3
- 241001465754 Metazoa Species 0.000 abstract description 2
- 238000002474 experimental method Methods 0.000 abstract description 2
- 230000007246 mechanism Effects 0.000 abstract description 2
- 230000003248 secreting effect Effects 0.000 abstract description 2
- 230000004936 stimulating effect Effects 0.000 abstract description 2
- 238000004873 anchoring Methods 0.000 abstract 1
- 210000002865 immune cell Anatomy 0.000 abstract 1
- 230000003393 splenic effect Effects 0.000 abstract 1
- 239000000047 product Substances 0.000 description 30
- 230000009182 swimming Effects 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 108020004414 DNA Proteins 0.000 description 10
- 230000006037 cell lysis Effects 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 9
- 238000012637 gene transfection Methods 0.000 description 7
- 101710139410 1-phosphatidylinositol phosphodiesterase Proteins 0.000 description 6
- 102100037097 Protein disulfide-isomerase A3 Human genes 0.000 description 6
- 238000001962 electrophoresis Methods 0.000 description 6
- 102100037850 Interferon gamma Human genes 0.000 description 5
- 108010074328 Interferon-gamma Proteins 0.000 description 5
- 238000000246 agarose gel electrophoresis Methods 0.000 description 5
- 238000010166 immunofluorescence Methods 0.000 description 5
- 101150084750 1 gene Proteins 0.000 description 4
- 241000208340 Araliaceae Species 0.000 description 4
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 4
- 235000003140 Panax quinquefolius Nutrition 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 235000008434 ginseng Nutrition 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 210000004988 splenocyte Anatomy 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000012407 engineering method Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 150000003905 phosphatidylinositols Chemical class 0.000 description 2
- 229940067626 phosphatidylinositols Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- 230000008521 reorganization Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 101100008044 Caenorhabditis elegans cut-1 gene Proteins 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101000981253 Mus musculus GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229940030156 cell vaccine Drugs 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 102000057593 human F8 Human genes 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229940047431 recombinate Drugs 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 101150033897 sea gene Proteins 0.000 description 1
- 230000007651 self-proliferation Effects 0.000 description 1
- 238000012882 sequential analysis Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 231100000617 superantigen Toxicity 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
Images
Landscapes
- Peptides Or Proteins (AREA)
Abstract
The invention provides the preparation and application of mB7.1-GPI fusion protein, an eukaryotic expression system (pcDNA3.1(+)-mB7.1-GPI) of B7.1(mB7.1-GPI), preparing mB7.1-GPI fusion proteins. They can anchor on tumor cell membrane, and the experiment proves that the anchoring has considerably stability; keeps bioactivity of immune protein, and has the functions of stimulating multiplication of mice splenic cells and secreting IL-2 and IFN-Y genes. The mB7.1-GPIs anchor the tumor cells to make tumor vaccine able to inhibit tumor growth of tumor-bearing mice and prolong the living time of the tumor-bearing mice, and its mechanism has relation with the activity of animal immune cells NK and CTL in tumor vaccine enhancement test and the cell genes IL-2 and IFN-gama secreted.
Description
Affiliated field
The invention belongs to biotechnology, relate generally to the preparation of glycosylation phosphatidylinositols grappling type mouse B7.1 fusion rotein and the preparation and the application aspect oncotherapy of this fusion protein film finishing knurl seedling.
Background technology
Antitumor knurl seedling is the main policies of tumor immune gene therapy, and to carrying out finishing to strengthen its immunogenicity and immunizing potency from body or allogeneic tumor cell, the knurl seedling is modified and mainly realized by the gene transfection means at present in knurl seedling preparation process.As Hodge etc.
[1]With expressing in the B7.1 gene importing tumour cell, costimulating factor is provided, can strengthen the anti tumor immune response of knurl seedling; Shrayer etc.
[2]With SEA gene transfection mouse B16 melanoma cell, make it to express SEA, use this oncocyte and make the knurl seedling, shown stronger antitumor action.
Though the gene transfection method plays very vital role on tumor immune gene therapy, the gene transfection method also has its limitation
[3], be difficult for transfection as primary cell, transfection efficiency is low, integrate the unstable of the degraded of back gene and expression thereof and prepare time-consuming and clinical application difficult.Therefore be necessary to seek and be suitable for primary cell transfection, transfection efficiency height, easy, the clinical infection protocol of easily applying of preparation.
By genetic engineering means with glycosylation phosphatidylinositols (GPI) and target protein matter chimeric expression, Zhi Bei target protein mass-energy enough anchors on the various kinds of cell film thus, does not thisly make method that target protein expresses on target cell membrane albumen infection protocol (protein transfer) by the gene transfection means
[4]
The albumen infection protocol has many advantages
[4]: (1) does not rely on cell self proliferation potential and transfection, so can be used for the transfection of multiple primary cell, has nothing to do with the type of cell and the source of histoorgan; (2) also there are certain difficulty in the cotransfection of complex gene and coordinate expression in same cell, and the albumen transfection can allow multiple protein simultaneously or in a sequence to be anchored on cell surface, are suitable for the preparation of multiple immune molecule film finishing knurl seedling; (3) external, the immune molecule that can be used for the albumen transfection by a large amount of preparations of gene engineering method, after these immune molecules and patient's autologous tumor cell are hatched jointly, can prepare knurl seedling more easily through the autologous tumor cell of immune molecule finishing, need not in autologous tumor cell, to do individual gene transfection, therefore bigger clinical application potentiality are arranged.
This research prepares mB7.1-GPI by gene engineering method, is anchored to mouse T cell lymphoma cell (EL-4), prepares the knurl seedling, observes its antitumor action.The method domestic and foreign literature that this research prepares mB7.1-GPI does not all have report.
Summary of the invention
An object of the present invention is to prepare the mB7.1-GPI fusion rotein, SEQ ID NO:1 is the nucleotide sequence of mB7.1-GPI fusion gene.
Another object of the present invention is by the albumen infection protocol, and the mB7.1-GPI fusion rotein is anchored on the oncocyte film, and the preparation surface of cell membrane is modified the knurl seedling.
The present invention is anchored to mouse T cell lymphoma cell (EL-4) with the mB7.1-GPI fusion rotein, preparation knurl seedling.
The method that the present invention prepares the mB7.1-GPI fusion rotein mainly may further comprise the steps:
(1) make up hPLAP-1 the 11st exon cloning vector pGEM-hPLAP-1 11exon (it comprises GPI grappling signal sequence), as template, amplification GPI grappling signal sequence.
(2) NSX-mB7-1 is a template, amplification mB7-1 gene extracellular region sequence.
(3) utilize the SOEing reaction, two sequences that increase are coupled together.
(4) make up carrier for expression of eukaryon pcDNA3.1 (+)/mB7.1-GPI of this junction fragment, order-checking is correct.
(5) use the liposome transfection method, with pcDNA3.1 (+)/mB7.1-GPI transfection in Chinese hamster ovary celI, with G418 screening G418 resistance clone, with flow cytometry, screening positive clone screens a high-expression clone, and its positive rate is 96.6%, fluorescence intensity is 34.8, names this clone to be CHO/pcDNA3.1 (+)-mB7.1-GPI.
(6) with immunoaffinity chromatography method purifying expressing protein, analyze the about 67KDa of demonstration purified product molecular weight through SDS-PAGE and Western Blot.
Another purpose of the present invention is the application of knurl seedling aspect oncotherapy of making,
MB7.1-GPI fusion rotein provided by the invention has film grappling function, mB7.1 can be anchored on the tumor cell membrane altogether, and have suitable stability.
Characteristics of the present invention are: mB7.1-GPI can be anchored on the tumor cell membrane, experimental results show that this grappling has suitable stability; The biologic activity that has kept immune protein simultaneously is in the external function that stimulation mouse boosting cell propagation is arranged and secrete IL-2, the IFN-γ factor.MB
7-1-GPI grappling tumour cell, the knurl seedling of making, can suppress the tumor growth of tumor-bearing mice and prolong survival time of tumor-bearing mice, its mechanism and knurl seedling strengthen laboratory animal immunocyte NK and CTL activity and immune stimulating activity emiocytosis IL-2, the IFN-gamma cells is factor-related.
Description of drawings
The agarose gel electrophoresis of Fig. 1 hPLAP-1 gene the 11st exon PCR product
The recombinate gel electrophoresis of pGEM-hPLAP-1 11exon plasmid DNA and double digestion product thereof of Fig. 2
The sequencing result of Fig. 3 pGEM-hPLAP-1 11exon
1% agarose gel electrophoresis of Fig. 4 PCR product
The gel electrophoresis that Fig. 5 pGEM-mB7.1-GPI enzyme is cut product
Fig. 6 pcDNA3.1 (+)/mB7.1-GPI enzyme is cut the gel electrophoresis of product
The sequencing result of Fig. 7 pcDNA3.1 (+)/mB7.1-GPI
Fig. 8 mB7.1 antigen is expressed in the Chinese hamster ovary celI with gene transfection
The immunofluorescence laser confocal microscope observations of Fig. 9 rotaring redyeing gene Chinese hamster ovary celI
Chinese hamster ovary celI surface mB7.1 expression of results before and after Figure 10 PI-PLC handles
The mCD80-CNBr-Separose 4B affinitive layer purification of Figure 11 mB7.1-GPI
Figure 12 SDS-PAGE analyzes Chinese hamster ovary celI mB7.1-GPI Expression of Fusion Protein and purification result (Coomassie blue stain)
Figure 13 Western Blot analyzes Chinese hamster ovary celI mB7.1-GPI Expression of Fusion Protein and purification result
The immunofluorescence laser confocal microscope observations of Figure 14 mB7.1-GPI grappling EL-4 cell
The tumor growth curve of Figure 15 tumor-bearing mice after accepting different preparation for treating
Active detect (the LDH method for releasing) of the different preparation for treating group of Figure 16 mouse NK
The CTL activity (LDH method for releasing) of the different preparation for treating group of Figure 17 mouse
The lifetime of Figure 18 tumor-bearing mice after accepting different preparation for treating
Embodiment
The present invention is further illustrated below in conjunction with embodiment and accompanying drawing, and non-limiting the present invention.
All related datas all adopt the SPSS software package to carry out statistical analysis in this experiment, and survival rate relatively adopts the Log-rank check, and other measurement data adopts variance analysis (F check) and relatively q check in twos.
The structure of purifying one hPLAP-1 the 11st exon cloning vector of structure, expression and the product of embodiment one mB7.1-GPI gene eukaryotic expression vector:
1. hPLAP-1 gene the 11st exon size of the electrophoretic analysis pcr amplification of amplification hPLAP-1 gene the 11st exon product is 307bp, 1.5% agarose gel electrophoresis result is referring to Fig. 1, wherein M:100bp dna molecular size indicates., the PCR product of swimming lane 1:hPLAP-111 exon.
2. the enzyme of reorganization pGEM-hPLAP-1 11exon plasmid DNA is cut and is identified reorganization pGEM-hPLAP-1 11exon plasmid DNA EcoRI and XhoI double digestion, enzyme is cut product with 1.5% agarose gel electrophoresis, the goal gene size is 307bp, the result is referring to Fig. 2, wherein M1, M2:DNA molecular size are marked, the PCR product of swimming lane 1:hPLAP-1 11 exons, the enzyme of swimming lane 2:pGEM-hPLAP-1 11 exons is cut product.
3. the sequential analysis of amplification gene
HPLAP-1 gene the 11st exon sequence
[4]See Genbank (M19159.1), the standard sequence among our sequencing result (referring to Fig. 3) and the Genbank (M19159.1) shows that relatively upstream 200bp and standard sequence are in full accord.The GPI grappling signal peptide gene sequence of hPLAP-1 C-terminal is positioned at upstream 150bp, so hPLAP-1 gene the 11st exon sequence of being cloned can be used for the structure of mB7.1-GPI fusion gene.
Two, the structure of the cloning and expression carrier of mB7.1-GPI gene
1. the electrophoretic analysis of amplification mB7.1 gene film outskirt product
With the pLNSX-mB7-1 plasmid DNA is template, with primer P3 and P4, the mB7.1 that pcr amplification goes out to be used for to be connected with hPLAP-1 gene the 11st exon GPI grappling signal peptide gene sequence fragment is because of film outskirt fragment, size is 761bp, referring to Fig. 4, wherein M1, M2:DNA molecular size sign, the PCR product of swimming lane 1:hPLAP-1 grappling signal peptide sequence, the PCR product of swimming lane 2:mB7.1 gene extracellular region sequence; The PCR product of swimming lane 3:mB7.1-GPI gene order.
2. the electrophoretic analysis of the GPI grappling signal peptide sequence of amplification coding hPLAP-1 gene
With pGEM-hPLAP-1 11exon plasmid DNA is template, amplifies the fragment of the GPI grappling signal peptide sequence of coding hPLAP-1 gene with primer P5 and P6, and size is 155bp, and electrophoresis result is referring to Fig. 4.
3.mB7.1-GPI the electrophoresis of fusion gene PCR product is identified
PCR product with above-mentioned 1,2 is a template, and with primer P3 and P6 amplification membrane grappling type costimulatory molecules mB7.1-GPI fusion gene, its size is 891bp, and electrophoresis result is referring to Fig. 4.
4.pGEM-mB7.1-GPI and the enzyme of pcDNA3.1 (+)/mB7.1-GPI is cut evaluation
Cloning vector pGEM-mB7.1-GPI and expression vector pcDNA3.1 (+)/mB7.1-GPI are behind EcoRI and XhoI double digestion, the goal gene size is 891bp, enzyme is cut 1% agarose gel electrophoresis result of product referring to Fig. 5,6, M:DNA molecular size sign among Fig. 5, the enzyme of swimming lane 1:pGEM-mB7.1-GPI plasmid is cut product; M:DNA molecular size sign among Fig. 6, swimming lane 1:pcDNA3.1 (+) plasmid, the enzyme of swimming lane 2:pcDNA 3.1 (+)/mB7.1-GPI plasmid is cut product, swimming lane 3:pcDNA3.1 (+)/mB7.1-GPI plasmid.
The sequencing result of (5.pcDNA3.1+)/mB7.1-GPI
Through with Genbank in mB7.1 gene (GeneBank X60958) sequence
[5]Compare with hPLAP-1 gene order (M19159.1), this research clone's mB7.1-GPI fusion gene comprises the gpi signal peptide-coding sequence (referring to Fig. 7) of mB7.1 gene film outskirt encoding sequence and hPLAP-1 gene.
Three, the expression and purification of mB.1-GPI fusion gene
(1) the Chinese hamster ovary celI clone's of expression mB.1-GPI fusion rotein qualification result
1.FCM behind art: pcDNA3.1 (+)/mB7.1-GPI transfection CHO cell, chosen 30 G418 resistance clones, FCM detects the expression of mB7.1.The positive expression of 13 strains, positive rate 21.9%~96.6%, the positive intensity of mean fluorecence is 4.76~34.8; Wherein the expression of 1 strain is higher than other positive expression strains, and for efficiently expressing the clone, positive rate is 96.6%, and average fluorescent strength is 34.8 (referring to Fig. 8), names this clone to be CHO/pcDNA3.1 (+)-mB7.1-GPI.No mB7.1 expresses in the Chinese hamster ovary celI of wild Chinese hamster ovary celI and empty carrier pcDNA3.1 (+) transfection, the Chinese hamster ovary celI called after CHO/pcDNA3.1 (+) of transfection empty carrier pcDNA3.1 (+).
2. the immunofluorescence laser confocal microscope is observed: CHO/pcDNA3.1 (+)-mB7.1-GPI cell climbing sheet, the laser confocal microscope of immunofluorescence is observed, see that surface of cell membrane is green fluorescence (FITC mark) (referring to Fig. 9), illustrate that the mB7.1-GPI fusion rotein is the film expression type, wild Chinese hamster ovary celI, CHO/pcDNA3.1 (+) cell are negative.
3.PI-PLC result: CHO/pcDNA3.1 (+), CHO/pcDNA3.1 (+)-mB7.1-GPI cell is handled through PI-PLC, and FCM detects PI-PLC
[6]The variation of cell surface mB7.1 before and after handling, the result shows: cell surface did not all have the expression of mB7.1 before and after CHO/pcDNA3.1 (+) cell PI-PLC handled; CHO/pcDNA3.1 (+)-mB7.1-GPI cell is after PI-PLC handles, and the mB7.1 The positive expression rate reduces to 9.46% from 96.6%, and fluorescence intensity reduces to 4.68 from 34.8, and referring to Figure 10, wherein (a) is for before handling, (b) for after handling.
(2) purifying protein qualification result (SDS-PAGE and Western Blot analyze)
1. the immunoaffinity chromatography process is referring to Figure 11: elution process has only a main peak, illustrates that the antibody chromatography column is special figure.
2.SDS-PAGE and the purified product behind Western Blot result: CHO, CHO/pcDNA3.1 (+), CHO/pcDNA3.1 (+)-mB7.1-GPI product of cell lysis and CHO/pcDNA3.1 (+)-mB7.1-GPI product of cell lysis immunoaffinity chromatography is analyzed through SDS-PAGE (Coomassie blue stain) (ginseng Figure 12) and Western Blot (ginseng Figure 13).M among ginseng Figure 12: molecular weight of albumen sign, swimming lane 1: the m7.1-GPI albumen of purifying; Swimming lane 2:CHO product of cell lysis, swimming lane 3:CHO/pcDNA3.1 (+)/mB7.1-GPI product of cell lysis, swimming lane 4:CHO/pcDNA3.1 (+) product of cell lysis.Swimming lane 1 among ginseng Figure 13: the m7.1-GPI albumen of purifying, swimming lane 2:CHO product of cell lysis, swimming lane 3:CHO/pcDNA3.1 (+)/mB7.1-GPI product of cell lysis, swimming lane 4:CHO/pcDNA3.1 (+) product of cell lysis.
The result shows: the purified product of CHO/pcDNA3.1 (+)/mB7.1-GPI product of cell lysis and immunoaffinity chromatography can be seen the band of an about 67KDa of molecular weight; And this band does not all appear in CHO, CHO/pcDNA3.1 (+) product of cell lysis; The purity of purifying protein reaches more than 95%.
The applied research of embodiment two mB7.1-GPI fusion roteins
1.mB7.1-GPI fusion rotein is to the grappling effect of tumor cell membrane
MB7.1-GPI and EL-4 oncocyte are hatched, and the laser confocal microscope of immunofluorescence is observed and seen that surface of cell membrane is green fluorescence (referring to Figure 14), illustrates that mB7.1-GPI albumen can anchor on the EL-4 oncocyte film.MB7.1-GPI and EL-4 oncocyte are hatched behind the 4hr 4 ℃ jointly and are placed 0h, 4h or 8h, and FCM detects.The fluorescence intensity of 0h, 4h, 8h sample is respectively 13.7,12.7,10.6 after the grappling, and the positive cell number percentage is respectively 95.4%, 91.3%, 85%.4h, 8h sample and 0h sample relatively, fluorescence intensity and positive cell number percentage reduce not obvious, show that fusion rotein and EL-4 tumour cell are hatched after, can be anchored on the tumor cell membrane, and this grappling has suitable stability.The 4 ℃ of EL-4/mB7.1-GPI cells of placing the 0h samples and EL-4 cell are made tumour-cell vaccine through mitomycin deactivation (final concentration is 100ug/ml, 37 ℃, 5%CO2 incubation 1hr), are used for that lymphproliferation response and secrete cytokines detect and immunity
2. tumour cell knurl seedling stimulates the effect of mouse boosting cell propagation and secrete cytokines
The multiplication capacity (PI represents with proliferation index) of EL-4/mB7.1-GPI knurl seedling stimulation mouse boosting cell and the amount of secreting leukocytes mesonium-2 (IL-2) and IFN-(IFN-γ) are than EL-4 knurl height of seedling, and difference has significance (P<0.05).
Table 1 knurl seedling stimulates mouse boosting cell propagation and secrete cytokines ability
Group IL-2 IFN-γ PI
AEL-4 22.9±1.4 41±3.2 1.98±0.7
BEL-4/mB7.1-GPI
a 508.8±22.1 805±13.5?3.43±0.6
IL-2, IFN-γ: mean ± SD pg/ml, PI:mean ± SD,
aCompare with the A group
3. tumor vaccine is to the therapeutic action of tumor-bearing mice
3.1 tumor vaccine to the restraining effect of tumor-bearing mice tumor growth in the right hind subcutaneous injection 1 * 10 of C57BL/6 mouse
6Individual wild-type EL-4 cell.After 7-10 days, find to have palp tumour.Each organizes mouse Subcutaneous tumor upgrowth situation referring to Figure 15.The average tumor diameter of EL-4 knurl seedling treatment group mouse is organized less than PBS, but its differences does not have significance (P>0.05); The average tumor diameter of EL-4/mB7.1-GPI knurl seedling group mouse is little than EL-4 knurl seedling treatment group and PBS group, and difference has significance (P<0.05).
3.2 the NK activity of tumor-bearing mice splenocyte
Adopt the LDH method for releasing that the splenocyte of difference treatment group tumor-bearing mice is carried out the active detection of NK.Target cell is YAC-1, and the ratio of effector cell and target cell was respectively 25: 1,50: 1 and 100: 1.Referring to Figure 16, the result shows: EL-4/mB7.1-GPI knurl seedling group NK activity is high than EL-4 knurl seedling group and PBS group, and difference has significance (P<0.05).
3.3. the CTL activity of tumor-bearing mice splenocyte
3.4 the lifetime of tumor-bearing mice
Except being used to detect NK and active 3 mouse of CTL,, observe its lifetime to remaining 5 mouse.The result shows: EL-4 knurl seedling group (mean lifetime 40.2 ± 1.3 days) is compared with the PBS group and is prolonged slightly lifetime, but there was no significant difference (P>0.05); EL-4/mB
7-1-GPI knurl seedling group mouse (mean lifetime 58 ± 3.5 days) is compared with EL-4 knurl seedling group with the PBS group and prolongs lifetime, significant difference (P<0.05) is arranged, referring to Figure 18.
The partial reference document that the present invention relates to:
1.odge?JW,Abrams?S,schlom?J,et?al.Induction?of?antitumor?immunity?byrecombinant?vaccinia?viruses?expressing?B7-1?and?B7-2?costimulatorymolecules.Cancer?Res,1994,54:5552-5555.
2.hrayer?DP,Kouttab?N,Hearing?VJ,et?al.Immunization?of?mice?withmelanoma?cells?transfected?to?secrete?the?superantigen,staphylococcalenterotoxin?A.Cancer-Immunol-Immunother.1998?Mar;46(1):7-13
3.ykocinski?ML,Kaplan?DR,Medof?ME.Antigen-presenting?cellengineering.AJP?January,1996,148(1):1-16.
4.illan?JL.Molecular?Cloning?and?Sequence?Analysis?of?Human?PlacentalAlkaline?Phosphatase.J.Biol.Chem.1986,261(7):3112-3115.
5.Freeman GJ, GrayGS, GimmiCD, et al.Structure, Expression, and T CellCostimulatory Activity of the Murine Homologue of the Human BLymphocyte Activation Antigen B7.J Exp Med, 1991,174:625-6SEQ ID NO:1 mB7.1-GPI fusion gene sequence
1 atggcttgca?
attgtcagtt?
gatgcaggat?
acaccactcc?
tcaagtttcc?
agtccaagg
61 ctcattcttc?tctttgtgct?gctgattcgt?ctttcacaag?tgtcttcaga?tgttgatgaac
121?aactgtccaa?gtcagtgaaa?gataaggtat?tgctgccttg?ccgttacaac?tctcctcatg
181?aagatgagtc?tgaagaccga?atctactggc?aaaaacatga?caaagtggtg?ctgtctgtca
241?ttgctgggaa?actaaaagtg?tggcccgagt?ataagaaccg?gactttatat?gacaacacta
301?cctactctct?tatcatcctg?ggcctggtcc?tttcagaccg?gggcacatac?agctgtgtcg
361?ttcaaaagaa?ggaaagagga?acgtatgaag?ttaaacactt?ggctttagta?aagttgtcca
421?tcaaagctga?cttctctacc?cccaacataa?ctgagtctgg?aaacccatct?gcagacacta
481?aaaggattac?ctgctttgct?tccgggggtt?tcccaaagcc?tcgcttctct?tggttggaaa
541?atggaagaga?attacctggc?atcaatacga?caatttccca?ggatcctgaa?tctgaattgt
601?acaccattag?tagccaacta?gatttcaata?cgactcgcaa?ccacaccatt?aagtgtctca
661?ttaaatatgg?agatgctcac?gtgtcagagg?acttcacctg?ggaaaaaccc?ccagaagacc
721?ctcctgatag?caagaacaca?tacaccgcct?gcgacctggc?gccccccgcc?ggcaccaccg
781?acgccgcgca?cccggggcgg?tccgtggtcc?ccgcgttgct?tcctctgctg?gccgggaccc
841?tgctgctgct?ggagacggac?tgctccctga?ctagag
All quote in this application as a reference at all documents that the present invention mentions, just quoted as a reference separately as each piece document.Need not further to elaborate, believe and adopt the disclosed content in front, those skilled in the art can use to greatest extent, and these equivalent form of values fall within the application's appended claims institute restricted portion equally.In addition, the preferred specific embodiments of front should be understood that only to illustrate, but not limits the scope of the invention by any way.
Claims (6)
1.mB7.1-GPI the preparation of fusion rotein and application thereof is characterized in that: preparation mB7.1-GPI fusion rotein, SEQ ID N0:1 is the nucleotide sequence of mB7.1-GPI fusion gene.
2. the preparation of mB7.1-GPI fusion rotein according to claim 1 and application thereof is characterized in that: by the albumen infection protocol, the mB7.1-GPI fusion rotein is anchored on the oncocyte film, the preparation surface of cell membrane is modified the knurl seedling.
3. the preparation of mB7.1-GPI fusion rotein according to claim 2 and application thereof is characterized in that: the mB7.1-GPI fusion rotein is anchored to mouse T cell lymphoma cell (EL-4), preparation knurl seedling.
4. the preparation of mB7.1-GPI fusion rotein according to claim 1 and application thereof is characterized in that: the method for preparing the mB7.1-GPI fusion rotein mainly may further comprise the steps:
(1) make up hPLAP-1 the 11st exon cloning vector pGEM-hPLAP-1 11exon (it comprises GPI grappling signal sequence), as template, amplification GPI grappling signal sequence.
(2) pLNSX-mB7-1 is a template, amplification mB7-1 gene extracellular region sequence.
(3) utilize the SOEing reaction, two sequences that increase are coupled together.
(4) make up carrier for expression of eukaryon pcDNA3.1 (+)/mB7.1-GPI of this junction fragment, order-checking is correct.
(5) use the liposome transfection method, with pcDNA3.1 (+)/mB7.1-GPI transfection in Chinese hamster ovary celI, with G418 screening G418 resistance clone, with flow cytometry, screening positive clone screens a high-expression clone, and its positive rate is 96.6%, fluorescence intensity is 34.8, names this clone to be CHO/pcDNA3.1 (+)-mB7.1-GPI.
(6) with immunoaffinity chromatography method purifying expressing protein, analyze the about 67KDa of demonstration purified product molecular weight through SDS-PAGE and Western Blot.
5. the preparation of mB7.1-GPI fusion rotein according to claim 1 and application thereof is characterized in that: mB7.1-GPI fusion rotein provided by the invention has film grappling function, mB7.1 can be anchored on the tumor cell membrane altogether, and have suitable stability.
6. the preparation of mB7.1-GPI fusion rotein according to claim 1 and application thereof is characterized in that: the application of knurl seedling aspect oncotherapy of making.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA2003101087786A CN1544637A (en) | 2003-11-18 | 2003-11-18 | Method for preparing mB7.1-GPI fusion proteins and their uses |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA2003101087786A CN1544637A (en) | 2003-11-18 | 2003-11-18 | Method for preparing mB7.1-GPI fusion proteins and their uses |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1544637A true CN1544637A (en) | 2004-11-10 |
Family
ID=34334858
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2003101087786A Pending CN1544637A (en) | 2003-11-18 | 2003-11-18 | Method for preparing mB7.1-GPI fusion proteins and their uses |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1544637A (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100406564C (en) * | 2006-02-28 | 2008-07-30 | 浙江大学 | Method for preparing polygene transfection tumor cell strain and its tumor vaccine |
CN102391377A (en) * | 2011-11-01 | 2012-03-28 | 孙嘉琳 | Fusion protein capable of inducing and activating cancer targeting T-cells as well as preparation method and application of the fusion protein |
CN106755028A (en) * | 2016-12-24 | 2017-05-31 | 山东明鑫集团有限公司 | A kind of method for building up of the outer grappling expression vector of cell membrane |
WO2023088246A1 (en) * | 2021-11-17 | 2023-05-25 | 上海君赛生物科技有限公司 | Membrane surface protein containing gpi anchor region |
-
2003
- 2003-11-18 CN CNA2003101087786A patent/CN1544637A/en active Pending
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100406564C (en) * | 2006-02-28 | 2008-07-30 | 浙江大学 | Method for preparing polygene transfection tumor cell strain and its tumor vaccine |
CN102391377A (en) * | 2011-11-01 | 2012-03-28 | 孙嘉琳 | Fusion protein capable of inducing and activating cancer targeting T-cells as well as preparation method and application of the fusion protein |
CN102391377B (en) * | 2011-11-01 | 2013-11-06 | 孙嘉琳 | Fusion protein capable of inducing and activating cancer targeting T-cells as well as preparation method and application of the fusion protein |
CN106755028A (en) * | 2016-12-24 | 2017-05-31 | 山东明鑫集团有限公司 | A kind of method for building up of the outer grappling expression vector of cell membrane |
WO2023088246A1 (en) * | 2021-11-17 | 2023-05-25 | 上海君赛生物科技有限公司 | Membrane surface protein containing gpi anchor region |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7385045B2 (en) | Canine B7-1 nucleic acid molecules | |
CN1332748A (en) | Isolated nucleic acid molecules which encodt T cell inducible factors (TIFs), proteins encoded, and uses thereof | |
CN103314002A (en) | Consensus prostate antigens, nucleic acid molecule encoding the same and vaccine and uses comprising the same | |
CN1106846C (en) | Carcinostatic agents | |
KR20120125283A (en) | Nucleic acid molecules encoding rantes, and compositions comprising and methods of using the same | |
CN1668746A (en) | MUC-1 antigen with reduced number of VNTR repeat units | |
CN1544637A (en) | Method for preparing mB7.1-GPI fusion proteins and their uses | |
CN1236391A (en) | Method for producing recombinants intended for use in a complete malaria antigene gp 190/MSP1 | |
US20240011047A1 (en) | Cmv vectors and uses thereof | |
CA3216720A1 (en) | Co-expression of constructs and immunostimulatory compounds | |
CN1803846A (en) | Hybrid protein of p53 protein epitope(SQAMDDLMLS) and filobactivirus gene 8 protein and application thereof | |
JP2021180677A (en) | Polyepitope construct for use in immunotherapy | |
RU2507265C2 (en) | RECOMBINANT PLASMID DNA pCI-UB-POLYEPI CONTAINING EPITOPES OF TUMOUR-ASSOCIATED ANTIGENS FOR COLORECTAL CANCER AND METHOD OF ITS APPLICATION FOR STIMULATION OF SPECIFIC ANTITUMOUR IMMUNE RESPONSE AGAINST COLORECTAL CANCER CELLS | |
CN1332240A (en) | Superoxide dismutase-4 | |
CN111588843A (en) | Bi-molecular DNA vaccine of virus antigen-immune co-activator | |
CN1891829A (en) | Alpha (1,3) galactosyl transferase recombinant vector, virosome and its preparation and use | |
WO2020132595A1 (en) | Il-10-containing vaccines and uses thereof | |
CN1191088C (en) | Application of VMIP derivatives in medicine for treating AIDS and inflammation pathology | |
CN1189481C (en) | Human truncated recombination soluble TRAIL-170 protein and application for preparing tumour-curing medicine thereof | |
CN1709510A (en) | Vaccine composition containing modified dendritic cells | |
CN1753994A (en) | Vaccines | |
CN1171640C (en) | Liver cancer superantigen immunogene therapy agent | |
CN1141319C (en) | Method for efficiently expressing recombinant human interleukin 12 in eukaryotic cell | |
CN1219057C (en) | Cell factor CKLF-HIA with functions of hematopoietic stimulation and immunoregulation and its variant CKLF-HIB | |
WO2023057589A1 (en) | Novel immune regulator |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |